KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Revenue: 2017-2025

Historic Revenue for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $12.8 million.

  • Aquestive Therapeutics' Revenue fell 5.43% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 122.34%. This contributed to the annual value of $1.0 million for FY2024, which is 98.01% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Revenue of $12.8 million as of Q3 2025, which was up 28.03% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Revenue peaked at $20.1 million during Q2 2024, and registered a low of -$44.7 million during Q4 2024.
  • Over the past 3 years, Aquestive Therapeutics' median Revenue value was $12.8 million (recorded in 2025), while the average stood at $7.6 million.
  • In the last 5 years, Aquestive Therapeutics' Revenue soared by 300.00% in 2021 and then plummeted by 438.38% in 2024.
  • Aquestive Therapeutics' Revenue (Quarterly) stood at $11.1 million in 2021, then fell by 3.57% to $10.7 million in 2022, then grew by 23.63% to $13.2 million in 2023, then tumbled by 438.38% to -$44.7 million in 2024, then fell by 5.43% to $12.8 million in 2025.
  • Its Revenue stands at $12.8 million for Q3 2025, versus $10.0 million for Q2 2025 and $8.7 million for Q1 2025.